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Abstract: Innate immunity is the first line of defense against viral infection, and in turn, 
viruses have evolved to evade host immune surveillance. As a result, viruses may persist in 
host and develop chronic infections. Type I interferons (IFN-α/β) are among the most 
potent antiviral cytokines triggered by viral infections. Porcine reproductive and respiratory 
syndrome (PRRS) is a disease of pigs that is characterized by negligible induction of type I 
IFNs and viral persistence for an extended period. For IFN production, RIG-I/MDA5 and 
JAK-STAT pathways are two major signaling pathways, and recent studies indicate that 
PRRS virus is armed to modulate type I IFN responses during infection. This review 
describes the viral strategies for modulation of type I IFN responses. At least three 
non-structural proteins (Nsp1, Nsp2, and Nsp11) and a structural protein (N nucleocapsid 
protein) have been identified and characterized to play roles in the IFN suppression and 
NF-κB pathways. Nsp’s are early proteins while N is a late protein, suggesting that 
additional signaling pathways may be involved in addition to the IFN pathway. The 
understanding of molecular bases for virus-mediated modulation of host innate immune 
signaling will help us design new generation vaccines and control PRRS. 
Keywords:  arterivirus; interferon; PRRS; PRRSV; RIG-I; MDA5; NF-κB; JAK-STAT; 
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1. Introduction 
Porcine reproductive and respiratory syndrome (PRRS) is one of the most economically important 
diseases affecting the swine industry worldwide. The disease was first observed in the USA in 1987 
and then in Germany in 1990 [1]. The clinical signs include reproductive failures, including late-term 
abortions, increased number of stillborn and mummified fetuses in sows, and respiratory problems in 
pigs of all ages. The etiology of PRRS was first determined in 1990 in the Netherlands and named 
Lelystad virus (LV) [1]. Shortly after, porcine reproductive and respiratory syndrome virus (PRRSV) 
VR2332 was isolated in the USA and shown to be the sole causative agent for PRRS [1,2]. 
Comparative genomic sequence analyses reveal the genetic differences between LV and VR2332 and 
accordingly PRRS viruses are grouped into two genotypes; European (Type I) and North American 
(Type II) types [3,4]. A highly pathogenic PRRSV (HP-PRRSV) emerged in China in 2006 and was 
thought to be a mutant belonging to the North American type. Clinical studies show that the affected 
animals develop high fever, depression, anorexia, dyspnoea, reddening of the skin, edema of the 
eyelids, mild diarrhea, shivering, limping, and unusually high morbidity (50%–100%) and mortality 
(20%–100%) in pigs of all ages [5]. 
PRRSV belongs to the genus Arterivirus which is placed in the family Arteriviridae together with 
equine arteritis virus (EAV), lactate dehydrogenase-elevating virus of mice (LDV), and simian 
hemorrhagic fever virus (SHFV). The Arteriviridae family, along with the Coronaviridae and 
Roniviridae families, comprise the order Nidovirales [6–9]. The PRRSV genome consists of a   
positive-sense single-stranded RNA of 15 Kb in size, encoding 10 ORFs: ORF1a, ORF1b, ORF2a, 
ORF2b, ORFs 3 through 7, plus the newly identified ORF5a [10,11]. ORF1a and ORF1b code for two 
large polyproteins, pp1a and pp1a/b, with expression of the latter by ribosomal frame-shifting [12,13]. 
Pp1a and pp1a/b are proteolytically processed into 14 nonstructural proteins (Nsp’s) by the papain-like 
cysteine protease (PCP) in Nsp1, poliovirus 3C-like cysteine protease (CP) in Nsp2, and serine 
protease (SP) in Nsp4. Nsp3 through Nsp12 are cleaved by SP, and PCP generates Nsp1α and Nsp1ß, 
while CP generates Nsp2 [14]. ORF2a, ORF2b, ORF3 through ORF7, and ORF5a code for seven 
structural proteins: glycoprotein (GP) 2, small envelop (E), GP3, GP4, GP5, membrane (M), 
nucleocapsid (N) proteins, and the newly identified ORF5a protein [15,16]. GP5 and M form a dimer, 
and GP2, GP3, and GP4 form a hetero-trimer that may facilitate the virus entry [17,18]. N protein 
binds to the viral genome RNA and also interacts with itself to form the core capsid by 
homo-oligomerization during the viral particle assembly [19,20]. Some of the PRRSV proteins are 
multi-functional and shown to play modulatory roles for host innate immunity [14,21]. Interferons 
(IFN) are potent immune responsive cytokines against invading viruses, and their modulations by 
PRRSV have recently been studied. Although their precise mechanisms of action remain to be further 
elucidated, PRRSV exhibits significant inhibition of type I IFN production in both virus-infected cells 
and pigs. The current review summarizes the innate immune signaling pathways of host and discusses 
the current knowledge as to how PRRSV interferes with the type I IFN signaling pathways in particular. Viruses 2012, 4 
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2. Signaling Pathways for Innate Immunity against Virus Infection 
IFNs are multifunctional cytokines that play important roles for antiviral defense and shaping 
adaptive immunity. IFNs are commonly classified into type I and type II. Type I IFNs are the main 
cytokines for innate immunity against viral infections and include various subtypes depending on the 
animal species. Type I IFNs in humans consists of 13 subtypes for IFN-α and a single subtype for IFN-
ß, -ω, -κ, and -ε [22]. Limitin/IFN-like 1 is an additional type I IFN-like cytokine recently identified in 
mice that also binds the type I IFN receptor [23]. Similar to humans, IFN-α in swine is encoded by as 
many as 17 functional genes. The IFN-δ-like molecule is found only in pigs and cattle and designated 
SPI IFN [24,25]. IFN-γ is the sole representative of type II IFN. While type I IFNs are produced in 
most cell types in response to different viruses, type II IFN is produced by limited types of cells 
including natural killer (NK) cells, activated T lymphocytes, macrophages, and neurons. Type III IFNs 
have recently been described as containing 3 subtypes IFN-λ1, IFN-λ2, and IFN-λ3, but their role in 
antiviral defense remains to be established [22]. Since type I IFNs are the most notable cytokines in the 
fight against viral infection at an early stage, a focus will be given to discuss how they are produced in 
virus-infected cells and act on neighbor cells to prevent the spread of virus (Figure 1). 
Figure 1. Signal pathways for type I IFN production and IFN stimulated gene expressions. 
Double-stranded RNA, single-stranded RNA, and CpG DNA are recognized by TLR3, 
TLR7/8, and TLR9, respectively, in the endosomes, which leads to the dimerization of 
receptors and recruitment of TRIF or MyD88. The stimulation results in the assembly of 
signaling complexes and initiation of signaling cascades leading to the phosphorylation and 
activation of IRF3/IRF7, NF-κB, and AP-1. Once activated, these transcription factors 
translocate to the nucleus, and together with CBP, induce the transcription of IFN-α and 
IFN-β. Activation of RIG-I/MDA5 by viral RNA may be inhibited by LGP2. Both RIG-I 
and MDA5 activates IPS-1 through the CARD domain. IPS-1 then induces signaling 
pathways resulting in the activation of IRF3, IRF7, and NF-κB through different adaptors 
and kinases. IPS-1 signaling also likely involves the MAP kinase cascade for activation of 
AP-1. The nuclear signal of IRF3/IRF7, NF-κB, and AP-1 is similar to that of TLR. Once 
IFN-α and IFN-β are secreted extracellularly outside the cell after production, they bind to 
IFN receptors on itself (autocrine) or neighbor cells (paracrine), the receptor associated 
JAK1 kinase is phosphorylated and activated to recruit STAT1 and STAT2 through their 
SH2 domain for phosphorylation. The phosphorylated STAT1 and STAT2 are detached 
from the IFN receptors and associated each other to form ISGF3 complexes along with 
IRF9. ISGF3 then undergoes nuclear translocation and binds to ISRE to induce the 
transcription of hundreds of ISGs. Five major kinds of ISGs are listed here; MxA, 
OAS-1/RNaseL, RIG-I/MDA5, ISG15, and PKR. For their modes of action, see the text. 
Grey circle indicates the lysine-48-linked ubiquitin chain which leads to the degradation of 
proteins. Yellow circle indicates phosphorylation. Viruses 2012, 4 
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2.1. Toll-Like Receptor (TLR) Signaling 
Toll-like receptors (TLRs) have been investigated extensively in the past few years and a 
considerable progress has been made for mammalian TLRs and their functions. TLRs are a family of 
proteins recognizing different pathogen-associated molecule patterns (PAMPs). The key signaling 
domain unique to the TLR system is the toll/interleukin (IL)-1 receptor (TIR) domain located in the 
cytosolic face of each TLR and also in the adapters [26]. Once engaged to TLRs, PAMPs recruit 
different kinases through different adaptors by the TIR domain and thus trigger different signaling 
pathways, leading to the expression of specific genes that are involved in the removal of invading 
viruses. Ten TLRs have so far been identified for humans and 11 TLRs for mice [27]. Of these, TLRs 
3, 7, 8, and 9 are discussed in this review since they contribute the most to the control of virus 
infection [28].  
ssRNA    Short dsRNA 
TLR7/8 
TLR9 
TLR3 
Mitochondrion 
IPS‐1 
RIG‐I 
CpG‐DNA   Long dsRNA 
MDA5 
LGP2 
IRF7 
IRF3 
AP‐1 
p65  p50 
NF‐κB 
TRIF 
Endosome 
CBP 
IRF7 
IRF3 
IRF3 
AP‐1 
p65  p50 
NF‐κB 
Jak1  Tyk2 
IFNR   
S
T
A
T
1
 
IRF9 
S
T
A
T
2
 
S
T
A
T
1
 
IRF9 
S
T
A
T
2
 
ISRE 
ISGF3 
IFN‐β 
IFN‐α 
Nucleus 
Cytoplasm  
ISG15 
Protein 
modifica on 
MxA 
Inhibi on of viral 
trafficking 
PKR 
Inhibi on of 
transla on 
RIG‐I 
MDA5 
PRRS 
2’5’‐OAS 
RNaseL 
RNA degrada on 
MyD88 
IFNα/β   
IFNα/β   
ISGs transcripts 
ISGs 
First wave  Second wave 
PIAS Viruses 2012, 4 
 
 
428
2.1.1. TLR3 
Most cell types express TLR3 in the intracellular endosomes, except human fibroblast in which 
TLR3 is found to act on the cell surface [29]. TLR3 mediates the response to both poly(I:C) and 
dsRNA [30,31]. After stimulation, the TIR domain of TLR3 binds to the TIR-containing adaptor 
protein inducing IFN-ß (TRIF) which indirectly activates several transcription factors including NF 
(nuclear factor)-κB, IRF (interferon regulation factor) 3, and AP (activating protein)-1 [32]. To 
mediate IRF3 activation, the N-terminal domain of TRIF associates with TANK-binding kinase-1 
(TBK-1)/IκB kinase-ε (IKK-ε) through NF-κB activating kinase (NAK)-associated protein 1 (NAP1) 
and tumor necrosis factor (TNF) receptor-associated factor 3 (TRAF3) to phosphorylate IRF3, which 
then forms a dimer to translocate to the nucleus for IFN-ß expression [32]. For NF-κB activation, TRIF 
binds to TRAF6 and receptor-interacting protein 1 (RIP1). TRAF6 is an ubiquitin ligase and thus 
ubiquitinylation of RIP1 by TRAF6 is recognized by TAK (transforming growth factor ß-activating 
kinase) binding protein 2 (TAB2) and TAB3, leading to activation of TAK1 and then phosphorylation 
of IKKα and IKKß. These two activated kinases then phosphorylate IκBα which undergoes 
degradation by ubiquitinylation and releases NF-κB to the nucleus [33]. TAK-1 also activates MAPK 
(mitogen-activated protein kinase), c-Jun N-terminal kinase, p38, and extracellular signal-regulated 
kinase, which leads to phosphorylation and activation of the members of the AP-1 family [32], which 
also triggers IFN-ß gene transcription.  
2.1.2. TLR7/8/9 
TLR7/8 recognize dsRNA as short as 19-21 bps in size. TLR7/8 are constitutively expressed at high 
levels in specific peripheral blood mononuclear cells (PBMCs). TLR7 in human is highly expressed in 
plasmacytoid dendritic cells (pDCs) whereas TLR8 is mainly found in monocytes [34]. TLR9 senses 
unmethylated CpG DNA in the genome in DNA viruses, which induces the production of type I IFN in 
pDCs [35]. All three TLRs are anchored on the endosomal membranes [28]. Different from TLR3 
which uses TRIF as a primary adaptor, TLR7/8/9 use MyD88 to induce IFN expression [36]. For 
TLR7/8, the signaling starts with the MyD88 binding to TRAF6 and IRAK-1 (IL-1 reporter associated 
kinase 1). This complex leads to the IRF-5 and IRF-7 activation [37]. Similarly, TLR9 also causes 
MyD88 to interact with IRF7 with the help of a kinase complex containing TRAF6 and IRAK-1 or 
IRAK-4. For different functions in different cell types, different family members of IRAK are 
involved. In pDCs, IRAK-1 is required while IRAK-4 is responsible in HEK cells [38]. Interestingly, 
IRF7 can also interact with either MyD88 or TRAF6 [39]. For IRF7 activation, the IRF7/IRAK-1 
complex leads to the IRAK-1-mediated IRF7 phosphorylation. The phosphorylated IRF7 then 
dimerizes and translocates into the nucleus mainly for IFN-α expression. In this process, IKKα, which 
is known to participate in the NF-κB activation, is essential. Thus, the IRAK4-IRAK1-IKKα kinase 
cascades may lead to the IRF7 activation [39]. In summary, the TLR7/8 and TLR9 pathways in the 
endosome activate IRF7 through MyD88 and account for production of IFN-α in pDCs, which plays a 
crucial role during virus infection. The TLR3-mediated IRF3 and NF-κB activation through TRIF is an 
additional scenario to induce IFN-ß gene expression, which may present an alternative role in anti-viral 
immunity, especially for RNA viruses including PRRSV. Viruses 2012, 4 
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2.2. Cytoplasmic Receptors and Their Signaling 
2.2.1. RIG-I/MDA5 Pathway 
Retinoic acid inducible gene I (RIG-I) is an intracellular receptor for viral dsRNA. It contains a  
C-terminal DExD/H box-RNA helicase domain and two N-terminal caspase recruitment domains 
(CARDs) through which RIG-I induces type I IFN. Only RNA molecules that can be efficiently 
recognized and unwound by the helicase domain of RIG-I have the potential to induce type I IFN 
through CARD. Therefore, the helicase domain of RIG-I acts as a switch to control whether CARD is 
revealed and available for activation of downstream processes [34]. Once the CARD domain of RIG-I 
is uncovered by conformational changes under stimulation, another CARD-containing protein IFN-ß 
promoter stimulator-1 (IPS-1) is recruited as an adaptor through CARD-CARD interaction. The 
CARD-CARD interaction between RIG-I and IPS-1 is essential for dsRNA-induced activation of   
NF-κB, IRF3, and IRF7 [40]. For IRFs activation, IPS-1 transduces signals through TRAF3, a 
signaling factor involved in the TLR-activation pathway, which in the case of the RIG-I-IRF pathway 
associates with NEMO and TANK to facilitate the recruitment of TBK1 and IKKε to form the   
IPS-1-TRAF complex. This complex leads to TBK1/IKKε activation, which then phosphorylates IRF3 
and IRF7. Phosphorylated IRF3 and IRF7 form homo- or hetero-dimer and are transported to the 
nucleus. For NF-κB activation, IPS-1 interacts with TRAF2, TRAF6, and RIP1, which is similar to 
TLR3-activated NF-κB activation [38]. Once in the nucleus, the active form of IRF3 or IRF7, NF-κB, 
AP-1, together with other co-transcription factors, such as CREB-binding protein (CBP) form an IFN 
enhanceosome to produce IFN-ß and IFN-α [39]. 
An important question is the relative importance of signaling mediated by RIG-I versus TLRs. 
Gene-knockout studies show that RIG-I and TLR pathways mediate different antiviral signaling in 
different cell types. The ability to induce IFN-ß is severely compromised in RIG-I knockout 
conventional DCs and fibroblasts, whereas the IFN-ß induction is absolutely normal in RIG-I knockout 
plasmacytoid DCs, but not in the absence of MyD88 and TRIF [41]. Overall, RIG-I and TLR pathways 
are not redundant, but rather sense the virus in multiple ways in different cell types so that the host can 
fight against the virus more efficiently. Besides RIG-I, MDA5 and LPG2 have also been identified as 
DExD/H box RNA helicase that functions in the antiviral immune response. Like RIG-I, MDA5 
contains two N-terminal CARD domains and promote the IFN-ß induction. In contrast, LPG2 lacks the 
CARD domain and thus is considered as a negative regulator in the RIG-I pathway [42,43]. 
2.2.2. IPS-1 Signaling  
IPS-1 has been proven to play an essential role in the antiviral signaling pathway. Over-expression 
of IPS-1 leads to activation of both IRF3 and NF-κB and thus type I IFN production. Besides the 
N-terminal CARD domain, IPS-1 also contains a proline (PRO) region and a C-terminal hydrophobic 
transmembrane (TM) region that anchors to the mitochondrial outer membrane [37,44]. Mutational 
analysis shows that the CARD and TM domains are both essential for IPS-1 to retain its function. The 
mislocalization of IPS-1 greatly impairs the ability to induce IFNs [37], suggesting the involvement of 
mitochondria in innate immunity. IPS-1 is also able to interact with Fas-associated death domain 
(FADD) or to directly bind to the C-terminal region of IKKα and IKKβ kinases to activate NF-κB. Viruses 2012, 4 
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Both FADD and mitochondria have the ability to induce the apoptosis pathway through recruiting 
apoptotic factors and releasing pro-apoptotic proteins, respectively. This hints that apoptosis may be 
one of the innate immune responses and IPS-1 may act as a bridge between apoptosis and type I 
IFN response. 
2.2.3. RNA Recognition by RIG-I and MDA5 
RIG-I and MDA5 are cytoplasmic receptors to recognize RNA. They are structurally similar, but 
functionally different. Studies show that MDA5 is essential for the recognition of picornaviruses and 
poly(I:C) [45,46]. RIG-I is required for the recognition of many negative-strand RNA viruses 
including Sendai virus and influenza A virus, and poly(I:C) is often used to stimulate the RIG-I/MDA5 
pathway [46]. Compared to MDA5, RIG-I senses RNA transcribed in vitro by polymerases. Actually, 
both single- and double-strand RNA with a triphosphate moiety at the 5' end can activate type I IFN 
production via RIG-I [47,48]. This leads to a crucial question ‘How the host or such cytoplasmic 
receptors distinguish viral RNAs from self-RNAs’. The answer is not hard but complicated. Cellular 
RNAs like ribosomal RNA (rRNA) and transfer RNA (tRNA) possess a 5' monophosphate instead of 
5' triphosphate and thus would not be detected by RIG-I. For messenger RNA (mRNA) and small 
nuclear RNAs (snRNAs) however, the 5' end is modified with a methyl-guanosine cap which protects 
RNAs from degradation. In addition, cellular RNAs are often post-transcriptionally modified by 
pseudouridine, 2-thiouridine, or 2'-O-methylation, and these modifications suppress the immune-
stimulatory activity of RNA even if the RNA contains a 5' triphosphate [33,48]. Last but not least, 
cellular RNA generally does not exist as “naked” molecules in a cellular environment but rather forms 
complexes with a multitude of RNA-binding proteins. Thus, it is conceivable that protein components 
of the complexes may also play a role in marking certain RNA species as ‘self’ [33]. 
2.3. IFN Signaling Pathways 
After the first wave of IFN-ß production, the response enters into the second stage, where hundreds 
of genes are upregulated and the resulting proteins are involved in a variety of functions. These genes 
are referred to as IFN-stimulated genes (ISGs), and the pathway that transduces the IFN signal for 
expression of ISGs is the JAK-STAT pathway. 
2.3.1. JAK-STAT Pathway 
The JAK-STAT signaling pathway is initiated when IFN-α and IFN-ß bind to their receptors on the 
cell surface. The receptor binding activates Janus kinase (JAK) and Tyk2 to phosphorylate the signal 
transducers and activators of transcription 1 (STAT1) and STAT2. Phosphorylated STAT1 and STAT2 
form heterodimers which associates with IRF9 to form the interferon-stimulated gene factor 3 (ISGF3) 
complex. The ISGF3 complex is imported into the nucleus and binds to IFN stimulated response 
element (ISRE) to induce ISGs resulting in the establishment of an antiviral state. Once the ISGF3 
complex translocates to the nucleus, both phosphorylated STAT1 and STAT2 undergo 
dephosphorylation and are redistributed back to the cytoplasm [49]. Viruses 2012, 4 
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The JAK-STAT pathway is regulated by feedback inhibitors of three STAT negative regulators. 
The suppressor of cytokine signaling (SOCS) family suppresses the phosphorylation of STATs by 
inhibiting the association of JAK with the IFN receptors [50]. The protein inhibitor of activated STATs 
(PIAS) family consists of PIAS1, PIAS3, and PIASy. PIAS1 and PIAS3 compete against STAT1 and 
STAT3 for ISRE within the promoter region, respectively, and thus suppress the expression of 
ISGs [51]. PIASy can recruit other factors to repress the transcription activities of STAT1. In addition 
to the negative regulation of STATs, PIAS is also identified as a SUMO E3 ligase. SUMO is a small 
ubiquitin-like modifier and many proteins are post-translationally modified by SUMO, which is a 
process known as sumoylation. Sumoylation occurs similarly to ubiquitinylation in such a way that a 
SUMO molecule is conjugated to its target protein through specific sequence recognition by E3 
ligase [52].  Sumoylation  plays  roles in diverse biological processes including regulation of gene 
transcription, chromatin structure, protein localization and functions. SUMO E3 ligase is required for 
ubiquitinylation of certain proteins and mediates degradation. 
2.3.2. IFN Inducible Genes and Their Functions 
More than 300 ISGs have been identified so far but a relatively few of these ISGs have been 
implicated in instigating the antiviral state including catalysis of cytoskeletal remodeling for apoptosis, 
regulation of post-transcriptional events, and post-translational modifications. Many other ISGs 
function as pattern-recognition receptors (PRRs) to sense viral molecules or encode transcription 
factors that participate in the amplification loop increasing IFN production and preventing 
dissemination of virus [53]. Among all ISGs, ISG15, GTPase, myxovirus resistance A (MxA), 
ribonuclease L (RNaseL), and protein kinase K (PKR) are the most extensively studied, and function 
as antiviral effectors. 
ISG15: ISG15 is an ubiquitin homolog [54]. Since ubiquitylation is involved in innate immune 
signaling, ISGylation mediated by ISG15 is thought to have IFN regulatory function. ISG15 is 
expressed as a 165-amino acid protein and processed to expose the C-terminal LRLRGG sequence. 
When this sequence is exposed in the case of ubiquitylation, ubiquitin is conjugated to its substrate by 
three enzymes; ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2), and ubiquitin 
ligase enzyme (E3) [55]. For ISGylation, ISG15 is conjugated to its substrates by similar to or even the 
same enzyme. The E1-like ubiquitin-activating enzyme is specific for ISG15, whereas E2 ubiquitin-
conjugating enzyme and E3 ubiquitin ligase possess the ability to conjugate and ligate both 
ubiquitin and ISG15. At least 158 putative ISG15 substrates have been identified and many of them 
play  important roles for type I IFN responses including JAK1, STAT1, RIG-I, Mx1, and PKR 
functions [53]. Similar to ubiquitylation, ISGylation is also reversible. However, unlike the Lys48-
linked ubiquitin leading to proteasomal degradation, ISGylation parallels the K63-linked ubiquitin to 
recruit other proteins and modulates the function of enzymes. ISGylation can prevent virus-mediated 
IRF3 degradation [56]. ISG15 may also be secreted outside cells in a large amount and act as a 
cytokine to modulate immune responses [57]. 
Mx: Type I IFNs induce the expression of several quinine-hydrolysis proteins. The Mx family of 
proteins belongs to this class of proteins involved in mediating vesicle budding, organogenesis, and 
cytokinesis, but only MxA in humans has been shown to have an antiviral activity [58,59]. The Mx Viruses 2012, 4 
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proteins have a large N-terminal GTPase domain, a center interacting domain (CID), and a C-terminal 
leucine zipper (LZ) domain. Both the CID and LZ domains are required to recognize target viral 
structures mostly nucleocapsid-like structures [60]. In normal circumstances, the MxA protein 
accumulates on the intracellular membrane and forms oligomers by association between the LZ and 
CID domains. During virus infection, MxA monomers are released and bind to viral nucleocapsids or 
other viral components and trap them for degradation. 
OAS1: 2', 5'-oligoadenylate synthetase 1 (OAS1) is constitutively expressed in cells at low levels 
and upregulated by type I IFNs. OAS1 resides in the cytoplasm as an inactive monomer. Once 
activated by viral RNA, this enzyme oligomerizes and forms a tetramer which synthesizes 2′-5′ linked 
oligoadenylates (2-5A). The binding of 2-5A to RNase L triggers the dimerization of RNase L 
enabling it to cleave cellular and viral RNAs. The cleaved RNAs then activate cytoplasmic PRRs such 
as RIG-I and MDA5 [53,61]. 
PKR:  PKR belongs to a family of protein kinases that respond to environmental stresses and 
regulate protein syntheses [62]. PKR is constitutively expressed in all tissues at basal levels and 
up-regulated by type I and type III IFNs [63]. Under normal circumstance, PKR remains as an inactive 
monomer. During infection, viral RNA elicits a conformational change of PKR and allows ATP to 
bind to its C-terminal kinase domain for activation. Activated PKR dimerizes and phosphorylates 
eukaryotic initiation factor 2α (EIF2α) to halt the translational process [53]. Two RNA-binding motifs 
(RBMs) are found in the N-terminal region of PKR, and these motifs bind RNA by recognizing a 
specific higher ordered structure. Longer RNA moieties engage both RBMs of PKR and activate the 
kinase function, although RNAs binding to PKR need only be 16 bps long [64]. Consequently, 
dsRNAs longer than 30 bps activate PKR efficiently and ssRNA of 47 bases with a 5'-triphophate have 
a limited ability to active PKR [65].  
In general, ISG15 and MxA are expressed only after IFN stimulation, whereas OAS-RNaseL and 
PKR are expressed constitutively at low levels but increased by type I IFN stimulation. Constitutive 
expressions of OAS and PKR suggest that these proteins act not only as effectors but also as dsRNA-
specific PRRs that can trigger antiviral responses. 
3. Modulation of Innate Immunity by PRRSV 
In PRRSV-infected swine, the virus persists through a ‘smoldering’ type of infection in which the 
virus continuously replicates at a low level. The virus first develops an acute infection lasting for  
3 to 4 weeks followed by persistent infection in some animals. During persistent infection, viremia is 
absent and viral replication sites are restricted primarily to lymphoid tissues and other immune-
privileged sites such as tonsils and lymph nodes [66,67]. Persistence of PRRSV is also common in the 
semen of infected boars [68]. Virus shedding from persistently infected pigs is an important source for 
transmission and is one of the main factors that hinder the control of PRRSV infection in the field. 
Viral persistence may be the result of a poor immune response, including delayed production of 
neutralizing antibodies and suppression of innate immune responses. 
Recent studies have described cytokine responses during PRRSV infection. In PRRSV-infected 
pigs, TNF-α is down-regulated while IL-10 production is up-regulated. Pigs do not show typical innate 
immune responses including type I IFN response, although PRRSV is highly susceptible to IFN-α/β Viruses 2012, 4 
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and its growth is inhibited. PRRSV-infected pigs display low levels of IFN-α despite the abundant 
presence of viral RNA in infected cells. IFN-α is not detectable in the lungs of virus-infected pigs 
where PRRSV actively replicates [69,70]. The suppression of IFN production is also evident in 
virus-infected MARC-145 and PAM (porcine alveolar macrophage) cells [69,71,72], suggesting that 
PRRSV suppresses IFN production. Such inhibition by PRRSV is RIG-I mediated [73]. In pigs 
infected with the newly emerged highly pathogenic PRRSV (HP-PRRSV), the virus replicates rapidly 
and readily persists. RNA microarray analysis of HP-PRRSV-infected cells shows that production of 
swine type I IFNs are suppressed, suggesting that the host innate immune response is blocked [5]. The 
European genotype of PRRSV has also been examined by microarray analysis for its ability to 
modulate global gene expression [74]. A repression of IFN-α transcription and a delay of IFN-ß 
transcript accumulation in infected-microphages was shown. Here, we discuss below the manipulation 
of IFN signaling pathways by PRRSV during infection (Figure 2). 
3.1. TLRs and the Virus 
Although a large body of information is available for viral modulation of TLRs for humans, porcine 
TLRs are relatively poorly understood. TLR9 is expressed in Peyer’s patches in pigs, and its 
expression is also stimulated in monocyte-derived dendritic cells [75]. Porcine TLR3 and TLR7 seem 
to be important for PRRSV [76,77], and porcine TLR8 has also been identified. Porcine TLR3 is 
highly expressed in kidney, duodenum, spleen, and liver, whereas porcine TLR7 is moderately 
expressed in bone marrows, intestines, spleen, livers, lungs, mesenteric lymph nodes, trachea, thymus, 
kidneys, and skin [77]. Differential expressions of TLRs have been studied for PAMs and porcine bone 
marrow hematopoietic cell-derived immature dendritic cells (imDCs) in response to poly(I:C) and 
PRRSV [78]. In unstimulated cells, expression levels of TLR3, TLR7, and TLR8 were higher in PAMs 
than in imDCs. Poly(I:C) tends to stimulate the TLR3 expression in PAMs but inhibits TLR7 and 
TLR8 expression. In contrast, PRRSV down-regulates TLR3, TLR7, and TLR8 expression levels at  
6 h post-infection (p.i.) in imDCs, which return to basal levels by 24 h p.i.. Interestingly, TLR7 
expression decreased continuously through 24 h of infection. In other study, the TLR3 activation 
caused increased antiviral response to PRRSV and decreased viral replication [76]. TIR-domain 
truncated TLR3 was found to increase the PRRSV infection in MARC-145 cells, while wild-type 
TLR3 inhibited PRRSV replication. Thus, TLR3 seems to play an important role in establishing 
effective innate immunity to PRRSV. Another study [79] using poly(I:C) as a TLR3-specific agonist 
and LPS as a TLR4-specific agonist showed that PRRSV infection increased IFN-α expression at 16 h 
p.i. in PAMs, and this was an 8 h delay compared to poly(I:C) stimulation alone. No significant 
increase of IFN-α was observed upon infection [79]. When PRRSV-infected cells are stimulated by 
poly(I:C) or LPS, TLR4 was not influenced but TLR3 was significantly reduced, and the TLR3 
down-regulation facilitated virus replication. Viruses 2012, 4 
 
 
434
Figure 2. The modulation of type I IFN production by PRRSV. PRRSV has been shown to 
reduce the expression of TLR3 and IRF7 in pDCs. While Nsp1 has the ability to degrade 
CBP in the nucleus, Nsp1α subunit inhibits the IκB phosphorylation in the cytoplasm. 
Nsp2 inhibits IFN production by blocking the ubiquitinylation of phosphorylated IκB and 
phosphorylation of IRF3 through the OTU domain. Nsp11 suppresses IFN-β production 
through degradation of IPS-1 mRNA. For the second wave of IFN signaling, PRRSV 
Nsp1β blocks the phosphorylation of STATs and inhibits the nuclear translocation of 
ISGF3 complex. Nsp1 interacts with PIAS. Since PIAS is a multi-functional protein, Nsp1 
interaction may also modulate pathways other than the JAK-STAT pathway. PKR is 
redistributed during PRRSV infection. Nsp2 has the potential to deconjugate ISGylation. 
The GP5 protein induces apoptosis. Since Nsp1 is cotranslationally processed to Nsp1α 
and Nsp1β in PRRSV-infected cells, the uncleaved form of Nsp1 is unlikely to exist in 
virus-infected cells. It is unknown which subunit of Nsp1 interacts with PIAS and 
degrades CBP.  
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3.2. PRRSV Targeting IFN Enhanceosome through IRF-Mediated RIG-I/MDA5 Pathways 
The abundance of IFN-α and IFN-ß transcripts are unaffected by PRRSV infection in MARC-145 
cells [72], suggesting that PRRSV infection does not result in the induction of type I IFN production. 
The mRNA levels for IFN and enhanceosome genes were enhanced following tRNA treatment. 
However, during concurrent tRNA treatment and PRRSV infection, IFN-α, IFN-ß, ATF-2, and IRF3 
(but not NF-κB and JUN), were significantly reduced relative to tRNA treatment only [72], and this 
virus-mediated inhibition was via the RIG-I signaling pathway [73]. PRRSV activates NF-κB and 
AP-1 but inhibits IRF3 which is mapped upstream of RIG-I.  
PRRSV Nsp’s have been screened for type I IFN suppression, and four Nsp’s were identified to 
contain the suppressive activities: Nsp1, Nsp2, Nsp4, and Nsp11 [80]. Nsp1 contains the strongest 
potential to inhibit the IFN-ß promoter activity, and both Nsp11 and Nsp1ß have the ability to inhibit 
IRF3-mediated type I IFN production. The phosphorylation and nuclear translocation of IRF3 are 
inhibited by Nsp1ß. The mechanism for Nsp1-mediated IFN inhibition is partly due to the degradation 
of CREB (cyclic AMP responsive element-binding)-binding protein (CBP) in the nucleus [80], which 
disrupts the formation of enhanceosome crucial for IFN gene expression. The CBP degradation is 
proteasome-dependent but independent from the PCP activity of Nsp1 (Figure 2).  
Nsp2 also down-regulates type I IFN induction (Figure 2). Nsp2 is a membrane-anchored protein 
that contains a CP activity and a deconjugation activity associated with ovarian tumor (OTU) domain-
containing protease activity. While the deconjugation activity is suggested to function in ISGs and 
NF-κB signaling, the CP activity inhibits IRF3 phosphorylation and nuclear translocation [81]. The 
mechanism for the CP mediated-IRF3 deactivation is unknown. 
Nsp11 participates in the suppression of RIG-I signaling. Different from Nsp1 which is localized in 
the cytoplasm and the nucleus, Nsp11 expression is mainly cytoplasmic suggesting its main function is 
in the cytoplasm. Nsp11 contains a domain designated the NendoU domain and functions as an 
endoribonuclease [82]. The NendoU domain consists of two subdomains; subdomain A and subdomain 
B. Subdomain A contains active sites for endoribonuclease activity, while subdomain B is thought to 
maintain the overall structure of Nsp11. We have been studying the role of Nsp11 for IFN regulation 
and have found that Nsp11 blocks the phosphorylation of both IRF3 and IκB. This leads to the 
inhibition of the nuclear translocation of IRF3 and NF-κB, and as consequences, IFN production is 
inhibited. IPS-1 is an upstream component in the RIG-I pathway and is found to be degraded in 
Nsp11-expressing cells and PRRSV-infected cells (Figure 2). The IPS-1 degradation results in the 
inhibition of down-stream pathways which is likely the basis for suppression of IRF3 and NF-κB 
activation by Nsp11. Using a series of NendoU mutants, the relationship between IPS-1 degradation 
and NendoU activities was examined and the results indicate that the Nsp11 endoribonuclease activity 
is associated with the degradation of IPS-1 mRNA. 
3.3. Modulation of NF-κB Signaling by PRRSV 
3.3.1. Up-regulation of NF-κB by N protein 
Viruses may activate or inhibit the NF-κB signaling for their own benefits. The NF-κB signaling 
pathway may function as a protective response of the host to a virus, and thus, many viruses have Viruses 2012, 4 
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evolved to block NF-κB activation to evade host innate immunity. In this scenario, NF-κB signaling is 
inhibited by PRRSV which suppresses a type I IFN response. However, a study shows that NF-κB may 
be up-regulated by PRRSV at 36–48 h p.i. [83]. The NF-κB activation during this time of infection 
was dose-dependent and replication-dependent since UV-inactivated PRRSV did not up-regulate the 
response. In porcine pDCs, PRRSV promotes NF-κB phosphorylation when stimulated with 
transmissible gastroenteritis virus (TGEV) [84]. The data show that PRRSV actually activates the 
NF-κB pathway in MARC-145 cells and PAMs at a late stage of infection. Activation of the NF-κB 
pathway by viruses may optimize viral replication and control of host cell proliferations and apoptosis. 
However, blocking NF-κB activation by over-expressing the dominant negative form of IκBα did not 
alter viral replication [73,83], suggesting that the activation of NF-κB by PRRSV may be involved in 
other cellular progresses such as apoptosis or modulation of cytokines. 
The PRRSV N protein appears to stimulate NF-κB activation and the activation is dose-dependent 
(Figure 2). The region at amino acid positions 30–73 of N is responsible for NF-κB activation, and 
within this region, both the nuclear localization signal (NLS) and nucleolar localization signal (NoLS) 
are located. Thus, it is plausible that NF-κB activation may be linked to the N protein nuclear 
localization. The region is also important for homo-dimerization of N, which is embedded in the 
NF-κB activation domain. This implies that N-N homo-dimerization may be associated with the 
NF-κB activation. 
3.3.2. Down-Regulation of NF-κB by Nsp1α and Nsp2 
During the course of our study, Nsp1α was found to be able to inhibit the activation of NF-κB [85]. 
This finding differs from the previous report [83]. Using the NF-κB and PRDII luciferase reporter 
constructs, Nsp1α was determined to reduce the luciferase activities of both reporters 24 h 
post-transfection. In the presence of Nsp1α, the phosphorylation of IκBα was inhibited, leading to the 
block of NF-κB nuclear translocation upon stimulation with tumor necrosis factor α (TNFα). Nsp1α is 
the N-terminal subunit of Nsp1 and contains the PCPα protease domain. A zinc finger motif is formed 
by four catalytic residues of histidine (H) or cysteine (C) to hold a zinc ion and is commonly found in 
transcription factors. PRRSV Nsp1α contains two zinc finger motifs; one motif (ZF1) of C8-C10-C25-
H28 and another motif (ZF2) of C70-C76-H146-M180. After cleavage, the PCPα activity is 
self-inactivated by conformational changes and thus is less likely responsible for suppression of the 
IFN response. This suggests that two zinc finger motifs may be associated with Nsp1α-mediated IFN 
suppression. A deletion mutant of Nsp1α lacking the C-terminal 14 amino acids, in which the second 
zinc finger motif is lost, shows no inhibition of IFN induction. This finding raises a possibility that 
zinc finger motifs of Nsp1α may take a part in the suppression of NF-κB or other type I IFN pathways. 
Using a series of mutant constructs, the first zinc finger motif has been mapped to be important for IFN 
regulation since the mutants containing the first zinc finger motif catalytic sites always reverse the IFN 
suppression [86]. Although it is unclear whether the CBP degradation by Nsp1 is mediated by Nsp1α 
or Nsp1β, it is possible that the cytosolic form of Nsp1 blocks the NF-κB activation and the nuclear 
form of Nsp1 degrades CBP possibly through the zinc finger domain. 
The OTU domain of Nsp2 is able to deconjugate the ubiquitin or ISG15 from substrates [87]. Since 
ubiquitinylation is involved in the RIG-I and TLRs signaling such as the recruitment of adaptor Viruses 2012, 4 
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proteins and degradation of IκBα, Nsp2 likely inhibits the type I IFN production via its OTU domain. 
Indeed, Nsp2 has been shown to be able to down-regulate the NF-κB activity although its mechanism 
is unknown [81]. Sun et al. [88] have reported that Nsp2 may interfere with polyubiquitinylation of 
phosphorylated IκB, resulting in the failure of IκB degradation. Further studies suggest that NF-κB 
may be down-regulated by Nsp’s at the early stage of virus infection. 
3.4. Inhibition of JAK-STAT Signaling and ISG Expressions by PRRSV 
PRRSV suppresses the type I IFN signaling not only during the production of IFNs but also after 
IFN secretion. In IFN-α-induced MARC-145 cells, the JAK-STAT pathway is suppressed at 24 h 
post-infection when using ISG15 and ISG56 mRNAs as indicators. The ISGF3 nuclear translocation is 
blocked by PRRSV [89]. In TGEV-stimulated pDCs, the nuclear translocation of STAT1 is inhibited 
by PRRSV [84], and Nsp1ß is the viral protein responsible for this inhibition. Nsp1ß, not Nsp1α, 
inhibits phosphorylation of STAT1 and nuclear translocation of ISGF3 [89,90]. In our laboratory by 
yeast-two-hybrid assays, Nsp1α has been found to interact with PIAS1 [91]. PIAS functions as a 
negative regulator for STAT1 and also as the SUMO E3 ligase. The interaction of Nsp1α with PIAS1 
may lead to the Nsp1α sumoylation and facilitate the Nsp1α transport into the nucleus. Besides, 
degradation of CBP by Nsp1 may also require the E3 ligase activity of PIAS. Nsp1 may bring CBP to 
PIAS1 and then CBP is sumoylated by PIAS1, which facilitates the ubiquitinylation of CBP for 
degradation. 
Less is known about the effects of PRRSV infection on ISGs. In MARC-145 cells, anti-PRRSV 
activity of type I IFNs is highly correlated with the MxA promoter activity and less correlated with 
IRF3 and IRF7 induction [25]. This suggests that MxA would be a better biomarker to monitor the IFN 
induction during PRRSV infection than other ISGs. ISG15 is an ubiquitin-like molecule and can be 
reversibly conjugated to proteins to mediate important innate antiviral responses. The OTU domain in 
Nsp2 of PRRSV contains a deubiquinylation activity. Nsp2 can decrease ubiquitinylation and 
ISGylation in 293T cells, indirectly indicating that Nsp2 may help the virus evade the innate immune 
response by deconjugation [87]. Typically, PKR is found in the both cytoplasmic and perinuclear 
regions in cell, but its distribution is altered by increased signals in the perinuclear region and within 
the nucleoli of PRRSV-infected cells. This localization pattern of PKR is similar to that of PRRSV N 
protein but N and PKR are not co-localized in the nucleoli [92].  
Combining the information, it seems that in the early stage of PRRSV infection, Nsp1, Nsp2, and 
Nsp11 facilitate viral gene transcription and viral protein translation, while suppressing the immune 
responses of infected cells by inhibiting type I IFN production and IFN-inducible signaling pathways. 
At 36 to 48 h p.i., when virus infection enters to the late stage, the NF-kB pathways are activated to 
assist the survival of virus in the host. 
3.5. Apoptosis and the Virus 
The autocrine and paracrine actions of type I IFNs and other cytokines encompass the 
comprehensive host immune response to defend against viral infection. This is accompanied by a 
reciprocal activation of programmed cell death in virus-infected cells and the reduction of viral load in 
the host. Apoptotic cells are observed in PRRSV-infected tissues of pigs [93], while in other studies, Viruses 2012, 4 
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apoptotic cells are not PRRSV-infected [94,95]. Based on the different observations, some researchers 
have reported that the GP5 protein expression induced apoptosis by acting downstream of B cell 
lymphoma-2 (Bcl-2) and mapped the apoptotic region to the N-terminal 119 amino acids of GP5 [96]. 
Other researchers however propose that ‘bystander’ cells undergo apoptosis during PRRSV infection 
supported by their microarray data in MARC-145 cells indicating that only minimal increases of 
pro-apoptotic gene transcripts in PRRSV-infected cells compared to uninfected cells [97]. Later, 
studies using porcine alveolar microphages [98] and monocyte-driven dendritic cells [99] reveal that it 
is the stage of virus infection that determines whether PRRSV-infected cells are towards anti-apoptosis 
or pro-apoptosis. At 8 h post-infection, the balance gears towards anti-apoptosis, but all infected cells 
will eventually die by both apoptosis and necrosis. The expression of viral proteins is necessary to 
induce a strong anti-apoptotic state and it is possible that non-structural proteins are involved in the 
apoptotic suppression since the PRRSV-mediated anti-apoptosis effect was already present before 
structural proteins were detectable in infected microphages [98]. As discussed earlier, both type I IFN 
production and virus-induced apoptosis are important defense mechanisms of a host against invading 
viruses and they both share common pathways. Therefore, it is possible that PRRSV may actively 
interfere with the induction of apoptosis, which may be partially due to its ability to inhibit type I IFN 
production, especially in the early stage of infection. 
IPS-1 interference is a good suggestion for PRRSV-mediated apoptosis. IPS-1 can induce the RIG-I 
signaling pathway, leading to the expression of type I IFNs and the mitochondria-mediated apoptosis. 
Studies indicate that IPS-1 functions as a bridge between the type I IFN induction and apoptosis. 
Nsp11 is able to degrade IPS-1 mRNA and results in the suppression of type I IFN induction. It is 
unknown whether the degradation of IPS-1 will also inhibit the cellular apoptosis. Nsp15 of severe 
acute respiratory syndrome coronavirus (SARS-CoV), which is the endoribonuclease homolog of 
PRRSV Nsp11, suppresses the IPS-1 induced apoptosis independent from IRF3 activation [100], 
implying that the IPS-1 suppression may lead to inhibition of apoptosis as a method of immune 
evasion for PRRSV. 
4. Conclusion and Future Prospects 
Innate immunity, especially the type I IFN signaling, is the first line defense of host cells to fight 
against virus infection. In the present review, multiple strategies of PRRSV for manipulating TLR and 
RIG-I-mediated IFN production and JAK-STAT signaling pathways are discussed. During the intricate 
signaling processes, other pathways including the NF-κB pathway are activated or inhibited by 
PRRSV. The N protein appears to activate the NF-κB pathway and its nuclear localization and 
dimerization may be associated. Nsp1, Nsp2, and Nsp11 are identified to be responsible for viral 
immune-modulation and their domains and motifs for biological mechanisms have partially been 
studied at the molecular level. Nsp1 interferes with the IRF3-mediated IFN production in the nucleus 
and the NF-κB-mediated pathway in the cytoplasm. For IFN signaling, the Nsp1ß subunit of Nsp1 
suppresses the JAK-STAT pathway by blocking different steps in different cell types. Besides, Nsp1 
(Nsp1α subunit or Nsp1β subunit, or both) interacts with PIAS1. Since PIAS is a nuclear protein with 
multiple functions, the interaction with PIAS opens a new direction of the host cellular modulation by 
Nsp1, which may or may not relate to IFN pathways. Nsp2 is involved in the blocking of IRF3 Viruses 2012, 4 
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activation through the activity of PCP2 and reduces ubiquitinylation and ISGylation through the OTU 
domain. Nsp11 degrades IPS-1 mRNA via the NendoU domain and impedes the downstream IRF3 and 
NF-κB activation. Despite the progress made on the PRRSV-mediated modulation of innate immune 
responses, studies have mainly been conducted in MARC-145 which are cells derived from monkey 
kidney, or in PRRSV non-permissive cells such as HeLa, raising questions as to their relevance to 
natural infection. Some limited studies have been conducted in PAMs as the natural target cells and 
pigs as the natural host animal. Different PRRSV isolates differ in their sensitivity to IFN-α and they 
also seem to have different abilities to down-regulate the IFN response [101]. Marked differences have 
been observed in different cell types for IFN-ß induction [102]. A vaccine strain of PRRSV does not 
exhibit sensitivity to IFN in MARC-145 cells, whereas both virulent PRRSV and the vaccine strain are 
sensitive to IFN in PAMs. The PKR inhibitor 2-aminopurine (2-AP) restored the virus replication in 
MARC-145 cells but did not rescue the virus in PAMs. In addition to different cell types and various 
virus isolates, different genetic breeds of pigs may yield different responses. PAMs from Landrace 
pigs inhibit or delay the PRRSV growth compared to those from other breeds of pigs [103]. The lack 
of knowledge on the mechanistic basis for how PRRSV evades host immune responses leads to an 
inadequate control of the disease. One of the key questions is whether the virulence of PRRSV is 
linked to immunosuppression. Identification of active sites for IFN modulation and generation of 
mutant PRRSV using infectious cDNA clones to eliminate the immune suppressive functions from the 
virus may be feasible ways to generate new and attenuated vaccines for PRRS. 
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